Abstract
It has been observed that the overproduction of Nitric Oxide (NO) causes disfunction of several organs and affects lactate level. Hence, attempts have been made to design and develop potent inhibitors for Nitric Oxide Synthases (NOSs), the enzymes which are responsible for its production. NOSs exist mainly in three different isoforms: neuronal, inducible, and endothelial, designated as nNOS, iNOS, and eNOS, respectively. For design and development of potent NOS inhibitors against all the 3 isoforms several Quantitative Structure-Activity Relationship (QSAR) studies were made. This article compiles comprehensively all such studies and discusses critically their outcome. For the inhibitors of all isoforms, some pharmacophore models have been developed in which commonly at least one H-bond donor, one H-bond acceptor, one hydrophobic group, and in some positively charged moieties have been found to be essential. Consistent to these pharmacophores, 2D and 3D QSAR studies have pointed out that all NOS inhibitors undergo H-bond, hydrophobic, electronic and steric interactions with the receptors.
Keywords: Nitric oxide synthase inhibitors, quantitative structure-activity relationships.
Current Enzyme Inhibition
Title:Quantitative Structure-Activity Relationship Studies on Nitric Oxide Synthase Inhibitors
Volume: 12 Issue: 1
Author(s): Satya P. Gupta, Harish Kumar and Basheerulla Shaik
Affiliation:
Keywords: Nitric oxide synthase inhibitors, quantitative structure-activity relationships.
Abstract: It has been observed that the overproduction of Nitric Oxide (NO) causes disfunction of several organs and affects lactate level. Hence, attempts have been made to design and develop potent inhibitors for Nitric Oxide Synthases (NOSs), the enzymes which are responsible for its production. NOSs exist mainly in three different isoforms: neuronal, inducible, and endothelial, designated as nNOS, iNOS, and eNOS, respectively. For design and development of potent NOS inhibitors against all the 3 isoforms several Quantitative Structure-Activity Relationship (QSAR) studies were made. This article compiles comprehensively all such studies and discusses critically their outcome. For the inhibitors of all isoforms, some pharmacophore models have been developed in which commonly at least one H-bond donor, one H-bond acceptor, one hydrophobic group, and in some positively charged moieties have been found to be essential. Consistent to these pharmacophores, 2D and 3D QSAR studies have pointed out that all NOS inhibitors undergo H-bond, hydrophobic, electronic and steric interactions with the receptors.
Export Options
About this article
Cite this article as:
P. Gupta Satya, Kumar Harish and Shaik Basheerulla, Quantitative Structure-Activity Relationship Studies on Nitric Oxide Synthase Inhibitors, Current Enzyme Inhibition 2016; 12 (1) . https://dx.doi.org/10.2174/1573408012666151126185958
DOI https://dx.doi.org/10.2174/1573408012666151126185958 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cellular Iron Homeostasis and Therapeutic Implications of Iron Chelators in Cancer
Current Pharmaceutical Biotechnology Progresses and Challenges in Optimization of Human Pluripotent Stem Cell Culture
Current Stem Cell Research & Therapy Arsenic Immunotoxicity and Immunomodulation by Phytochemicals: Potential Relations to Develop Chemopreventive Approaches
Recent Patents on Inflammation & Allergy Drug Discovery Interplay of Drug-Metabolizing Enzymes and Transporters in Drug Absorption and Disposition
Current Drug Metabolism Targeting Nodal and Cripto-1: Perspectives Inside Dual Potential Theranostic Cancer Biomarkers
Current Medicinal Chemistry Endocrine Disruptors and Human Health
Mini-Reviews in Medicinal Chemistry Leveraging Cell Cycle Analysis in Anticancer Drug Discovery to Identify Novel Plasmodial Drug Targets
Infectious Disorders - Drug Targets Indoleamine 2,3-Dioxygenase, an Emerging Target for Anti-Cancer Therapy
Current Cancer Drug Targets Nanoparticulate Drug Delivery to Colorectal Cancer: Formulation Strategies and Surface Engineering
Current Pharmaceutical Design Polyploid Giant Cancer Cells (PGCCs): The Evil Roots of Cancer
Current Cancer Drug Targets The Role of Co-Infections in Mother-to-Child Transmission of HIV
Current HIV Research Pregnancy, Programming and Preeclampsia: Gap Junctions at the Nexus of Pregnancy-induced Adaptation of Endothelial Function and Endothelial Adaptive Failure in PE
Current Vascular Pharmacology Covid-19 in Man: A Very Dangerous Affair
Endocrine, Metabolic & Immune Disorders - Drug Targets The Important Roles of miR-205 in Normal Physiology, Cancers and as a Potential Therapeutic Target
Current Cancer Drug Targets ADAM19/Adamalysin 19 Structure, Function, and Role as a Putative Target in Tumors and Inflammatory Diseases
Current Pharmaceutical Design Editorial: Drug Targets and Biomarkers for Obstetric/Gynecologic/Reproductive Diseases
Current Drug Targets Epigenetics: Relations to Disease and Laboratory Findings
Current Medicinal Chemistry The Role of Insulin-Like Growth Factor I Components in the Regulation of Vitamin D
Current Pharmaceutical Biotechnology Extrapituitary Actions of GnRH Antagonists: Prospects for in vitro Fertilization Programs
Current Pharmaceutical Design Properties of the Mesenchymal Endometriotic Stem Cell in the Context of the Immune System and Analysis of its Role in Endometriosis
Recent Patents on Regenerative Medicine